BR112014004297A2 - compostos para uso em reforço da coagulação - Google Patents

compostos para uso em reforço da coagulação

Info

Publication number
BR112014004297A2
BR112014004297A2 BR112014004297A BR112014004297A BR112014004297A2 BR 112014004297 A2 BR112014004297 A2 BR 112014004297A2 BR 112014004297 A BR112014004297 A BR 112014004297A BR 112014004297 A BR112014004297 A BR 112014004297A BR 112014004297 A2 BR112014004297 A2 BR 112014004297A2
Authority
BR
Brazil
Prior art keywords
compounds
coagulation enhancement
coagulation
enhancement
Prior art date
Application number
BR112014004297A
Other languages
English (en)
Other versions
BR112014004297B1 (pt
Inventor
Yildiz Cafer
Erik Hack Cornelis
Original Assignee
Umc Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umc Utrecht Holding Bv filed Critical Umc Utrecht Holding Bv
Publication of BR112014004297A2 publication Critical patent/BR112014004297A2/pt
Publication of BR112014004297B1 publication Critical patent/BR112014004297B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
BR112014004297-7A 2011-08-25 2012-08-24 Uso de um inibidor de antitrombina iii no tratamento ou prevenção de sangramento BR112014004297B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527140P 2011-08-25 2011-08-25
US61/527,140 2011-08-25
PCT/NL2012/050581 WO2013028070A2 (en) 2011-08-25 2012-08-24 Compounds for use in boosting coagulation

Publications (2)

Publication Number Publication Date
BR112014004297A2 true BR112014004297A2 (pt) 2017-03-28
BR112014004297B1 BR112014004297B1 (pt) 2021-12-14

Family

ID=46845975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004297-7A BR112014004297B1 (pt) 2011-08-25 2012-08-24 Uso de um inibidor de antitrombina iii no tratamento ou prevenção de sangramento

Country Status (14)

Country Link
US (1) US20140356377A1 (pt)
EP (1) EP2747776B1 (pt)
JP (2) JP6198277B2 (pt)
CN (1) CN103930129A (pt)
AU (1) AU2012299524B2 (pt)
BR (1) BR112014004297B1 (pt)
CA (1) CA2846494C (pt)
CY (1) CY1120688T1 (pt)
DK (1) DK2747776T3 (pt)
ES (1) ES2689776T3 (pt)
HU (1) HUE039590T2 (pt)
PL (1) PL2747776T3 (pt)
PT (1) PT2747776T (pt)
WO (1) WO2013028070A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35457A (es) 2013-03-14 2014-10-31 Bayer Healthcare Llc ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß
EP3904519A1 (en) 2014-10-30 2021-11-03 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and preparations for the treatment of diseases related to SERPINC1
EP3430059A1 (en) * 2016-03-18 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
JP6883899B1 (ja) * 2020-12-07 2021-06-09 株式会社血栓トランスレーショナルリサーチラボ 血液凝固検査試薬、および血液凝固検査方法
PL440675A1 (pl) * 2022-03-17 2023-09-18 Politechnika Wrocławska Związki do równoległego wykrywania i hamowania proteaz szlaku krzepnięcia - APC, trombiny, czynnika Xa i czynnika XIa w ludzkim osoczu

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748913A (en) * 1904-01-05 Fo model
JP2010533684A (ja) * 2007-07-20 2010-10-28 ユニベルシテ パリ サッド 11 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用
DE102011081871A1 (de) * 2011-08-31 2013-02-28 Henkel Ag & Co. Kgaa Oxazolidine zur Fehlgeruchsbekämpfung

Also Published As

Publication number Publication date
PL2747776T3 (pl) 2019-03-29
PT2747776T (pt) 2018-10-31
CA2846494A1 (en) 2013-02-28
BR112014004297B1 (pt) 2021-12-14
EP2747776A2 (en) 2014-07-02
AU2012299524A1 (en) 2014-03-13
WO2013028070A2 (en) 2013-02-28
CY1120688T1 (el) 2019-12-11
JP2014529606A (ja) 2014-11-13
CN103930129A (zh) 2014-07-16
JP2017186340A (ja) 2017-10-12
DK2747776T3 (en) 2018-09-17
US20140356377A1 (en) 2014-12-04
AU2012299524B2 (en) 2017-03-23
CA2846494C (en) 2020-10-20
JP6198277B2 (ja) 2017-09-20
ES2689776T3 (es) 2018-11-15
EP2747776B1 (en) 2018-07-11
WO2013028070A3 (en) 2013-04-18
HUE039590T2 (hu) 2019-01-28

Similar Documents

Publication Publication Date Title
CO6801796A2 (es) Composiciones de tratamiento de pozo de liberación retardada para uso en fluídos de tratamiento de pozo
CR20130677A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
BR112013030413A2 (pt) hastes para uso em artigos de fumo
CO6890100A2 (es) Tratamientos de combinación para hepatitis c
BR302012003126S1 (pt) Configuração aplicada em empunhadura para intrumento médico
BR112013032559A2 (pt) cookie em camads saudável
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
BRDI7106210S (pt) Configuração aplicada para lâmina para microscópio
BR112013031813A2 (pt) composição para aplicação tópica
CO6890075A2 (es) Alcoholimetro calibrable
BR112015002584A2 (pt) composição de lipossoma para uso em diálise peritonial
BR112013028128A2 (pt) composição de polímero para dispositivos elétricos
CO6920293A2 (es) Compuestos antibaterianos y método para su uso
BR112014004297A2 (pt) compostos para uso em reforço da coagulação
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
BR112013028282A2 (pt) composição de polímero para dispositivos elétricos
BR302012000605S1 (pt) Configuração aplicada em bloco de construção para crianças
BR112014004414A2 (pt) composições e métodos para tratar doença neurodegenerativa
BR112014022694A2 (pt) novos métodos e composições para o tratamento de doença
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
BR112014009370A2 (pt) combinações conservantes
BRDI7105327S (pt) Configuração aplicada em estojo para peças de dominó
BR112015004732A2 (pt) composto de piridinona para uso em terapia fotodinâmica
BR112013022474A2 (pt) aparelho de derivação para tanque de absorção
BR112013031220A2 (pt) composição tópica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2012, OBSERVADAS AS CONDICOES LEGAIS.